Neurocrine Biosciences Inc vs Raymond James Financial, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while Raymond James Financial, Inc. trades at $168.25 (market cap $32.80B). The key difference: Raymond James Financial, Inc. is the larger of the two by market cap, and Raymond James Financial, Inc. pays a 1.28% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | RJF | |
|---|---|---|
Market Cap | $17.40B | $32.80B |
Sector | Health | Financials |
52-Week High | $180.55 | $176.43 |
52-Week Low | $123.10 | $140.89 |
Enterprise Value | $16.49B | — |
Dividend Yield | — | 1.28% |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →